NCT03039023

Brief Summary

The investigators are interested in learning more about choline, a nutrient required by the body. The body does make some choline, but it does not make enough to support health and the rest must be acquired through diet. Eggs, and especially egg yolks, are a major dietary source of choline. Choline can also be given as a dietary supplement. Ingestion of choline supplements has been linked to an increased concentration of a compound called TMAO (trimethylamine N-oxide). Elevated TMAO levels have been linked to higher heart disease risk. With this study, the investigators hope to learn whether there is a difference in the way your body responds to the ingestion of a choline supplement versus the choline found within eggs.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
86

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 2, 2016

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

January 19, 2017

Completed
13 days until next milestone

First Posted

Study publicly available on registry

February 1, 2017

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 10, 2018

Completed
2.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 3, 2020

Completed
8 months until next milestone

Results Posted

Study results publicly available

May 14, 2021

Completed
Last Updated

November 4, 2025

Status Verified

October 1, 2025

Enrollment Period

1.6 years

First QC Date

January 19, 2017

Results QC Date

April 21, 2021

Last Update Submit

October 14, 2025

Conditions

Keywords

TMAOcholineeggsgastrointestinal microbiomehealthy volunteers

Outcome Measures

Primary Outcomes (2)

  • Changes in Plasma Levels of Fasting Trimethylamine-N-oxide (TMAO), a Choline Metabolite

    Changes in levels of non-labeled TMAO from baseline to end-of-study (day 28) as measured by established techniques by mass spectrometry.

    Baseline, 28 days

  • Changes in Platelet Function With Increased Choline Intake

    The activation and functioning of platelets within a single subject will be compared before and after increased choline intake.

    Baseline, Day 28

Secondary Outcomes (8)

  • Changes in Levels of Fasting Trimethylamine-N-oxide (TMAO) in 24-hour Urine Collections

    Baseline, Day 28

  • Changes in Plasma Levels of Fasting Choline

    Baseline, Day 28

  • Changes in Plasma Levels of Fasting Carnitine.

    Baseline, Day 28

  • Changes in Plasma Levels of Fasting Betaine.

    Baseline, Day 28

  • Changes in Lipid Profile, Total Cholesterol

    Baseline, Day 28

  • +3 more secondary outcomes

Study Arms (5)

Whole Hardboiled Eggs

EXPERIMENTAL

Subjects will consume four (4) pre-cooked, pre-peeled whole hardboiled eggs per day for 28 days.

Other: Pre-cooked, pre-peeled whole hardboiled eggs

Choline Bitartrate Tablets

EXPERIMENTAL

Subjects will consume two (2) 500mg choline bitartrate tablets per day for 28 days.

Dietary Supplement: Choline Bitartrate

Hardboiled Eggs + Choline Bitartrate Tablets

EXPERIMENTAL

Subjects will consume both four (4) whole, pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.

Dietary Supplement: Choline BitartrateOther: Pre-cooked, pre-peeled whole hardboiled eggs

Egg Whites + Choline Bitartrate Tablets

EXPERIMENTAL

Subjects will consume both the egg whites (no yolks) of four (4) pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.

Dietary Supplement: Choline BitartrateOther: Egg whites from pre-cooked, pre-peeled hardboiled eggs

Phosphatidylcholine Capsules

EXPERIMENTAL

Subjects will consume six (6) 420 mg phosphatidylcholine capsules by mouth per day for 28 days.

Dietary Supplement: Phosphatidylcholine capsules

Interventions

Choline BitartrateDIETARY_SUPPLEMENT

500mg choline bitartrate tablets

Choline Bitartrate TabletsEgg Whites + Choline Bitartrate TabletsHardboiled Eggs + Choline Bitartrate Tablets

Obtained from a commercial source.

Hardboiled Eggs + Choline Bitartrate TabletsWhole Hardboiled Eggs

Egg whites from pre-cooked, pre-peeled hardboiled eggs. The yolks are removed and discarded.

Egg Whites + Choline Bitartrate Tablets

420 mg phosphatidylcholine capsules obtained from a commercial source.

Phosphatidylcholine Capsules

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women age 18 years or above.
  • Willing to remain on aspirin or stay off aspirin or aspirin products for 1 week prior to starting the study and throughout the study period.
  • Able to provide informed consent and comply with study protocol.
  • Able to be off all other supplements during the study period.

You may not qualify if:

  • Significant chronic illness.
  • Active infection or received antibiotics within 1 month of study enrollment.
  • Use of over-the-counter probiotic within the past month
  • Chronic gastrointestinal disorders, such as ulcerative colitis or Crohn's disease.
  • Allergy to eggs or lactose.
  • Having undergone bariatric procedures or surgeries such as gastric banding or bypass.
  • Pregnancy.
  • Any condition that, in the judgment of the Investigator, would place a patient at undue risk by being enrolled in the trial or cause inability to comply with the trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

Location

Related Publications (4)

  • Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011 Apr 7;472(7341):57-63. doi: 10.1038/nature09922.

    PMID: 21475195BACKGROUND
  • Rebouche CJ, Chenard CA. Metabolic fate of dietary carnitine in human adults: identification and quantification of urinary and fecal metabolites. J Nutr. 1991 Apr;121(4):539-46. doi: 10.1093/jn/121.4.539.

    PMID: 2007906BACKGROUND
  • Bidulescu A, Chambless LE, Siega-Riz AM, Zeisel SH, Heiss G. Repeatability and measurement error in the assessment of choline and betaine dietary intake: the Atherosclerosis Risk in Communities (ARIC) study. Nutr J. 2009 Feb 20;8:14. doi: 10.1186/1475-2891-8-14.

    PMID: 19232103BACKGROUND
  • Wilcox J, Skye SM, Graham B, Zabell A, Li XS, Li L, Shelkay S, Fu X, Neale S, O'Laughlin C, Peterson K, Hazen SL, Tang WHW. Dietary Choline Supplements, but Not Eggs, Raise Fasting TMAO Levels in Participants with Normal Renal Function: A Randomized Clinical Trial. Am J Med. 2021 Sep;134(9):1160-1169.e3. doi: 10.1016/j.amjmed.2021.03.016. Epub 2021 Apr 17.

Related Links

MeSH Terms

Interventions

CholinePhosphatidylcholines

Intervention Hierarchy (Ancestors)

EthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesTrimethyl Ammonium CompoundsQuaternary Ammonium CompoundsOnium CompoundsGlycerophospholipidsPhosphatidic AcidsGlycerophosphatesPhospholipidsMembrane LipidsLipids

Limitations and Caveats

Small sample sizes within each group created uneven distributions of some baseline characteristics; participants' dietary intake beyond the assigned interventions was not controlled during the study period; using only healthy controls makes the translatability of the results to other patient populations, like those with impaired renal function, unclear.

Results Point of Contact

Title
Jennifer Wilcox
Organization
Cleveland Clinic Foundation

Study Officials

  • W. H. Wilson Tang, MD

    The Cleveland Clinic

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Staff, Cardiovascular Medicine, The Cleveland Clinic; Staff, Cellular and Molecular Medicine, The Cleveland Clinic Lerner Research Institute

Study Record Dates

First Submitted

January 19, 2017

First Posted

February 1, 2017

Study Start

September 2, 2016

Primary Completion

April 10, 2018

Study Completion

September 3, 2020

Last Updated

November 4, 2025

Results First Posted

May 14, 2021

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will not share

Locations